CHINA – Pivotal Life Sciences, a global investment firm dedicated to investing in companies involved in healthcare innovation seeking to improve patient outcomes, closed Pivotal bioVenture Partners Fund II, at $389m.
Fund II will continue Pivotal bioVenture Partners’ core strategy of investing in companies based in North America and Europe developing innovative and impactful therapeutics. Read more on VCWire.tech, our new website dedicated to the tech venture capital industry.18/12/2023
